Innoviva Past Earnings Performance

Past criteria checks 3/6

Innoviva's earnings have been declining at an average annual rate of -12.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 1.8% per year. Innoviva's return on equity is 9.7%, and it has net margins of 18.3%.

Key information

-12.5%

Earnings growth rate

-1.5%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate1.8%
Return on equity9.7%
Net Margin18.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Innoviva makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:HVE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2435365111-21
30 Jun 243301451130
31 Mar 243121811090
31 Dec 23310180980
30 Sep 23290508431
30 Jun 23290233830
31 Mar 23318233710
31 Dec 22331214580
30 Sep 22373293460
30 Jun 2240499210
31 Mar 22396188130
31 Dec 21392266160
30 Sep 21375309170
30 Jun 21365265170
31 Mar 21344253160
31 Dec 20337224120
30 Sep 2032221680
30 Jun 2029922890
31 Mar 20285189110
31 Dec 19261157150
30 Sep 19265375170
30 Jun 19261382130
31 Mar 19264399130
31 Dec 18261395190
30 Sep 18251190170
30 Jun 18238166240
31 Mar 18229147300
31 Dec 17217134320
30 Sep 17191101350
30 Jun 1717692320
31 Mar 1715072280
31 Dec 1613460230
30 Sep 1611338220
30 Jun 169319220
31 Mar 1671-4210
31 Dec 1554-19200
30 Sep 1538-39210
30 Jun 1526-56250
31 Mar 1516-68290
31 Dec 148-74350
30 Sep 143-66350
30 Jun 142-55320
31 Mar 142-9270
31 Dec 135-31240

Quality Earnings: HVE has a large one-off loss of $98.4M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: HVE's current net profit margins (18.3%) are higher than last year (17.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HVE's earnings have declined by 12.5% per year over the past 5 years.

Accelerating Growth: HVE's earnings growth over the past year (29.5%) exceeds its 5-year average (-12.5% per year).

Earnings vs Industry: HVE earnings growth over the past year (29.5%) exceeded the Pharmaceuticals industry 28.7%.


Return on Equity

High ROE: HVE's Return on Equity (9.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies